Scientific exchange · Dr. Emiko Tanaka

11 May 2026 · Virtual · Dr. Emiko Tanaka, Uniklinik Köln · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0005—

Capture insight from this engagement

Location: Uniklinik Köln
Therapeutic area: Oncology
Country: Germany
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Elderly / ECOG 2 patients
Brain-metastasis subgroup data
PD-L1 testing turnaround

Scientific content used

VTX core scientific deck v3.2
VOYAGE-1 pivotal data summary

Questions raised

Is there subgroup data for patients with untreated brain metastases?

Notes

Scientific exchange with thoracic medical oncologist at Uniklinik Köln. Discussed elderly / ecog 2 patients, brain-metastasis subgroup data, pd-l1 testing turnaround.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 2
Depth of exchange: 4
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0005

Audit history (0)

All create, update and approval events for this record

No audit events in sample data